Avid Bioservices (CDMO) Competitors $12.14 +0.21 (+1.76%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CDMO vs. UROV, RIGL, GTHX, PAND, MIRM, FOLD, HCM, ACAD, ZLAB, and MORShould you be buying Avid Bioservices stock or one of its competitors? The main competitors of Avid Bioservices include Urovant Sciences (UROV), Rigel Pharmaceuticals (RIGL), G1 Therapeutics (GTHX), Pandion Therapeutics (PAND), Mirum Pharmaceuticals (MIRM), Amicus Therapeutics (FOLD), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), Zai Lab (ZLAB), and MorphoSys (MOR). These companies are all part of the "medical" sector. Avid Bioservices vs. Urovant Sciences Rigel Pharmaceuticals G1 Therapeutics Pandion Therapeutics Mirum Pharmaceuticals Amicus Therapeutics HUTCHMED ACADIA Pharmaceuticals Zai Lab MorphoSys Urovant Sciences (NASDAQ:UROV) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations. Is UROV or CDMO more profitable? Urovant Sciences has a net margin of 0.00% compared to Avid Bioservices' net margin of -101.26%. Urovant Sciences' return on equity of 0.00% beat Avid Bioservices' return on equity.Company Net Margins Return on Equity Return on Assets Urovant SciencesN/A N/A -162.90% Avid Bioservices -101.26%-16.53%-5.60% Do analysts prefer UROV or CDMO? Avid Bioservices has a consensus target price of $13.63, indicating a potential upside of 12.23%. Given Avid Bioservices' stronger consensus rating and higher possible upside, analysts plainly believe Avid Bioservices is more favorable than Urovant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Urovant Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Avid Bioservices 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Does the media refer more to UROV or CDMO? In the previous week, Avid Bioservices had 5 more articles in the media than Urovant Sciences. MarketBeat recorded 5 mentions for Avid Bioservices and 0 mentions for Urovant Sciences. Avid Bioservices' average media sentiment score of 0.81 beat Urovant Sciences' score of 0.00 indicating that Avid Bioservices is being referred to more favorably in the news media. Company Overall Sentiment Urovant Sciences Neutral Avid Bioservices Positive Which has better valuation and earnings, UROV or CDMO? Avid Bioservices has higher revenue and earnings than Urovant Sciences. Avid Bioservices is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUrovant SciencesN/AN/A-$146.74M-$4.71-3.45Avid Bioservices$139.91M5.54-$140.75M-$2.27-5.35 Does the MarketBeat Community believe in UROV or CDMO? Avid Bioservices received 292 more outperform votes than Urovant Sciences when rated by MarketBeat users. Likewise, 66.07% of users gave Avid Bioservices an outperform vote while only 57.35% of users gave Urovant Sciences an outperform vote. CompanyUnderperformOutperformUrovant SciencesOutperform Votes7857.35% Underperform Votes5842.65% Avid BioservicesOutperform Votes37066.07% Underperform Votes19033.93% Which has more volatility & risk, UROV or CDMO? Urovant Sciences has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Do institutionals & insiders have more ownership in UROV or CDMO? 18.4% of Urovant Sciences shares are owned by institutional investors. Comparatively, 97.2% of Avid Bioservices shares are owned by institutional investors. 2.7% of Urovant Sciences shares are owned by company insiders. Comparatively, 3.1% of Avid Bioservices shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryAvid Bioservices beats Urovant Sciences on 13 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.Click here to discover our #1 crypto for the market right now – poised for massive growth Get Avid Bioservices News Delivered to You Automatically Sign up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDMO vs. The Competition Export to ExcelMetricAvid BioservicesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$774.41M$6.39B$5.06B$8.67BDividend YieldN/A8.04%5.06%4.06%P/E Ratio-5.3510.63100.7117.26Price / Sales5.54266.481,206.6171.28Price / Cash79.1053.4940.7536.36Price / Book4.029.306.325.87Net Income-$140.75M$154.14M$119.47M$225.66M7 Day Performance-0.98%-9.49%-5.11%-1.34%1 Month Performance19.02%-7.23%-3.21%1.00%1 Year Performance134.36%30.70%32.43%25.27% Avid Bioservices Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDMOAvid Bioservices3.4806 of 5 stars$12.14+1.8%$13.63+12.2%+134.4%$774.47M$139.91M-5.35371Positive NewsUROVUrovant SciencesN/A$16.24flatN/AN/A$531.75MN/A-3.1570RIGLRigel Pharmaceuticals3.9843 of 5 stars$27.41+0.7%N/A+197.5%$482.69M$116.88M195.80147Analyst ForecastNews CoverageHigh Trading VolumeGTHXG1 Therapeutics0.3878 of 5 stars$7.15flatN/AN/A$373.81M$58.20M-11.53170PANDPandion TherapeuticsN/A$60.05flatN/AN/A$1.77B$970,000.000.0056MIRMMirum Pharmaceuticals4.2693 of 5 stars$43.92+3.9%N/A+46.8%$2.10B$186.37M-21.74140Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews CoverageFOLDAmicus Therapeutics4.6701 of 5 stars$10.37-1.1%N/A-8.7%$3.10B$399.36M-30.50480Analyst ForecastShort Interest ↓HCMHUTCHMED1.5665 of 5 stars$17.04-2.5%N/A-4.7%$2.97B$838M0.001,988Short Interest ↓Positive NewsACADACADIA Pharmaceuticals3.988 of 5 stars$17.59-1.9%N/A-24.0%$2.93B$929.24M22.55510Analyst DowngradeShort Interest ↑ZLABZai Lab3.0075 of 5 stars$29.95+3.4%N/A+2.5%$2.88B$266.72M-10.812,175Analyst RevisionNews CoverageGap UpMORMorphoSys0.1404 of 5 stars$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies UROV Alternatives RIGL Alternatives GTHX Alternatives PAND Alternatives MIRM Alternatives FOLD Alternatives HCM Alternatives ACAD Alternatives ZLAB Alternatives MOR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CDMO) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avid Bioservices, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avid Bioservices With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
